BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,761.00
- Market cap
- ₹4,22,523 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 34.9×Sector 48.7×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharmaceutical Industries Credit Rating
Sun Pharma received credit ratings from CRISIL and ICRA for its proposed NCD programme and reaffirmed existing facility ratings.
Sun Pharmaceutical Industries Debt & Borrowing: ₹10,000 Cr
Sun Pharma's board approved issuing unsecured Non-Convertible Debentures up to ₹10,000 Crore. Additionally, Independent Director Mr. Gautam Doshi resigned from the company's board.
- Value
- ₹10,000 Cr
Other management change announcements
All →Amanta Healthcare Management Change
Amanta Healthcare's COO Shri Anil Rathi resigned effective October 29, 2026. The departure is disclosed under Regulation 30 of the SEBI Listing Regulations.
Mastek Management Change
Mastek Ltd appointed Mr. Niraj Khemka as Vice President – Finance. He will also lead Investor Relations for the company.
Bharat Road Network Management Change
Ms. Ankita Rathi has resigned from her position as Company Secretary and Compliance Officer of Bharat Road Network Limited, effective from October 29, 2026.
STL Networks Management Change
STL Networks Limited appointed Ms. Anshika Gupta as the new Company Secretary and Compliance Officer, effective October 30, 2026.
Suryoday Small Finance Bank Management Change
Suryoday Small Finance Bank announced that Mr. Ranjit Jayant Shah, Non-Executive Non-Independent Director, will cease to hold office effective November 2, 2026, upon tenure completion.
CARE Ratings Management Change
CARE Ratings Limited appointed Mr. Jatindar Pal Singh Bajaj as a Non-Executive Non-Independent Director, effective October 29, 2026.